Skip to content

Bern, Get Ready (BEready) Cohort Study for Pandemic Preparedness

Bern, Get Ready (BEready) Population-based Cohort Study for Pandemic Preparedness: Main Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06739499
Acronym
BEready
Enrollment
2157
Registered
2024-12-18
Start date
2024-04-29
Completion date
2100-12-31
Last updated
2026-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epidemic Disease, Infections, Pandemic, COVID-19, Respiratory Tract Infections, Zoonoses

Keywords

One Health, Pandemic preparedness, Community engagement

Brief summary

The BEready project aims to find out how people in the Canton of Bern can be helped to be more prepared for the next pandemic. BEready wants to understand how infections spread among people as well as between people and animals. BEready wants to find out how social and environmental factors can influence the transmission or catching of infectious diseases. BEready wants to better understand how households and their pets in the Canton of Bern were and continue to be affected by the coronavirus disease 2019 (COVID-19).

Detailed description

The overall aim is to establish BEready as a 'pandemic preparedness cohort', a cohort with a well-characterised study population of households, which has an infrastructure to conduct studies about infectious diseases, and which can be rapidly mobilised to respond to a new pandemic. BEready aims to understand the epidemiology and transmission of infectious diseases (particularly viral respiratory pathogens) in households including pets in the canton of Bern, and to engage diverse communities in efforts to strengthen pandemic preparedness. The objectives are: * to study the distribution and timing of infectious diseases and transmission patterns of circulating infectious diseases, both between individuals and at the human-animal interface (One Health) * to study social (e.g. gender, affective polarisation) and environmental factors (e.g. climate change), which may affect transmission or acquisition of infectious diseases; * to understand how households, including their pets, in the canton of Bern have been and will be affected by COVID-19; and * to engage diverse communities in ongoing efforts to strengthen pandemic and public health literacy, and to prepare for the public health response to a new pandemic.

Interventions

None listed

Sponsors

University of Bern
Lead SponsorOTHER
Stiftung Vinetum
CollaboratorUNKNOWN

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

for adults and children: * Informed consent * Residence (average of more than 3 days/week) in a private household in the canton of Bern where at least one member aged 18 agreed to take part. * For adults, children aged 14 years or older, and parents/legal guardians: internet connection (Wi-Fi, fixed or on a mobile phone) and personal email address. * For adults, children aged 11 years or older, and parents/legal guardians: able to understand, speak, read and write German, French and/or English. Inclusion criteria for household pets: Pets of eligible household members with the consent of their owners.

Exclusion criteria

for adults and children: Currently planned move outside the canton of Bern

Design outcomes

Primary

MeasureTime frameDescription
Attendance of follow up visits (to derive factors associated with research participation)At every annual follow-up for up to 100 yearsPercentage of completed questionnaire (study level)
Response rate among the randomly sampled participantsBaselinePercentage agreeing to take part, divided by the number invited, by age and sex (study level)
Incidence of respiratory virus detection in symptomatic personsAt the end of a 12 months periodTest positivity: percentage of nasal swab samples with a positive result for specific respiratory viruses among all viruses detected amongst those reporting disease events cumulatively by the end of one year; incidence rate for any detected virus and for specific viruses: number of nasal swab samples with a positive result per 100 person years of follow-up (individual level, infection-related)
Seroprevalence of antibodies to respiratory virusesAt baseline and annually thereafter for up to 100 yearsProportion of serum samples with antibodies to specific respiratory viruses (individual level, infection-related)
Incidence of co-infection/co-colonisation at the pet/owner interfaceThroughout follow-up for up to 100 yearsProportion of serum samples with antibodies to specific parasites (individual level, infection-related)
Incidence of animal diseases diagnosed through syndromic surveillanceThroughout follow-up for up to 100 yearsBased on each case definition, e.g. febrile illness, incidence of syndromic diagnoses by month (individual level, infection-related)
Prevalence of post-acute viral symptomsAt baseline and annually thereafter for up to 100 yearsIndividual level, infection-related
Gender rolesAt all timepoints for up to 100 yearsGender is a cross-cutting theme. Associations with gender measured by questionnaire will be examined for all endpoints (individual level, personal, social, demographic).
Number of daily social contactsAt baseline and annually thereafter for up to 100 yearsNumbers of social contacts between humans, according to age group and location (individual level, personal, social, demographic)
Affective polarisationAt baselineMean and standard deviation of Likert scale scores (individual level, personal, social, demographic)
Knowledge of pandemic preparednessAt baselineKnowledge measured by questionnaire. Summary of the survey data (individual level, personal, social, demographic)
Knowledge of vector-borne diseasesAt baselineKnowledge measured by questionnaire. Summary of the survey data (individual level, personal, social, demographic)
Experienced marginalisationAt baselineExperience measured by questionnaire. Summary of the survey data (individual level, personal, social, demographic)

Countries

Switzerland

Contacts

PRINCIPAL_INVESTIGATORNicola Low, Prof. Dr. med.

University of Bern

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026